Xinying Lu

1 Introduction Since its development in 1975, the hybridoma technique has become one of the most commonly used methods for monoclonal antibody discovery and production. Numerous hybridomas have been developed and widely applied in pharmaceuticals, clinical diagnostics and pollutant monitoring, creating a billion-dollar market and playing a critical role in safeguarding human health [1, 2].

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.